Preview

Медицинский Совет

Расширенный поиск

Безопасность терапии EGb 761® у коморбидных пациентов

https://doi.org/10.21518/2079-701X-2019-1-19-23

Полный текст:

Аннотация

В статье представлены данные различных исследований о частоте хронических заболеваний и состояний среди взрослых, что является серьезной проблемой общественного здравоохранения сегодня. Освещена проблема коморбидности в условиях демографического старения населения. Представлены результаты недавно проведенных исследований по частоте развития побочных явлений в зависимости от количества принимаемых лекарственных препаратов. Показано, что в пожилом возрасте еще одной проблемой становится развитие когнитивных нарушений. Описаны результаты выявляемости когнитивных нарушений среди пациентов стационаров общего профиля. Представлены данные об эффективности применения препарата из стандартизованного экстракта листьев гинкго билоба EGb 761® для профилактики и лечения когнитивных расстройств. Рассмотрен вопрос воздействия препарата EGb 761® у коморбидных пациентов, принимающих антиагреганты и антикоагулянты, на коагуляционные свойства крови.

 

 

Об авторе

Н. В. Пизова
Федеральное государственное бюджетное образовательное учреждение высшего образования «Ярославский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия
д.м.н., профессор, кафедра нервных болезней с медицинской генетикой и нейрохирургией Федерального государственного бюджетного образовательного учреждения высшего образования «Ярославский государственный медицинский университет» Министерства здравоохранения Российской Федерации


Список литературы

1. European Commission. Active ageing. [cited 2015 Jul 28]. Available from: http://ec.europa. eu/social/main.jsp?catId=1062.

2. The World Bank. Population ages 65 and above (% of total) [cited 2015 Jul 28]. Available from: http://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS.

3. Wilson P.W., D’Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 May;97(18):1837–1847.

4. McPherson K., Steel C.M., Dixon J.M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000 Sep;321(7261):624–628.

5. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047–1053.

6. National Council on Aging. Fact Sheet – healthy aging. [Accessed July 21 2015];2015 https://www.ncoa.org/wpcontent/uploads/ FactSheet_HealthyAging.pdf.

7. Jacob L., Breuer J., Kostev K. Prevalence of chronic diseases among older patients in German general practices. Ger Med Sci. 2016 Mar 3;14:Doc03.

8. Верткин А.Л., Зайратьянц О.В., Вовк Е.И. Окончательный диагноз. М., 2008.

9. Lehnert T., Heider D., Leicht H., Heinrich S., Corrieri S., Luppa M., Riedel-Heller S., König H.H. Review: health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev. 2011 Aug;68(4):387– 420.

10. Lankarani M.M., Assari S. Association between number of comorbid medical conditions and depression among individuals with diabetes; race and ethnic variations. J. Diabetes Metab. Disord. 2015;14(56):8.

11. Assari S. Cross-county variation in additive effects of socio-economics, health behaviors, and comorbidities on subjective health of patients with diabetes. J. Diabetes Metab. Disord. 2014;13(36):11.

12. Assari S., Lankarani M.M., Ahmadi K. Comorbidity influences multiple aspects of well-being of patients with ischemic heart disease. Int. Cardiovasc. Res. J. 2013;7(4):118–123.

13. Baumeister H., Balke K., Harter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. J. Clin. Epidemiol. 2005;58:1090–1100.

14. Diederichs C., Berger K., Bartels D.B. The measurement of multiple chronic diseases — a systematic review on existing multimorbidity indices. J. Gerontol. 2010;66A(3):301–311.

15. Prybys K.M., Melville K.A., Hanna J.R. Polypharmacy in the elderly: clinical challenges in emergency practice. Part I: overview, etiology, and drug interactions. Emerg Med Rep. 2002;1:145–51.

16. Reason B., Terner M., Moses McKeag A., Tipper B., Webster G. The impact of polypharmacy on the health of Canadian seniors. Fam Pract. 2012;29(4):427–32.

17. Hu T., Dattani N.D., Cox K.A., Au B., Xu L., Melady D., Jaakkimainen L., Jain R., Charles J. Effect of comorbidities and medications on frequency of primary care visits among older patients. Can Fam Physician. 2017 Jan;63(1):45-50.

18. Vogeli C., Shields A.E., Lee T.A., Gibson T.B., Marder W.D., Weiss K.B., Blumenthal D. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med. 2007 Dec;22 Suppl 3:391–395.

19. Wolff J.L., Starfield B., Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002 Nov;162(20):2269–2276.

20. Bickel H., Hendlmeier I., Heßler J.B., Junge M.N., Leonhardt-Achilles S., Weber J., Schäufele M. The Prevalence of Dementia and Cognitive Impairment in Hospitals. Dtsch Arztebl Int. 2018 Nov 2;115(44):733-740.

21. Abdel-Kader R., Hauptmann S., Keil U., et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761®). Pharmacol Res. 2007;56(6):493–502.

22. Tchantchou F., Xu Y., Wu Y., Christen Y., Luo Y. EGb 761® enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J. 2007;21(10):2400–2408.

23. Wu Y., Wu Z., Butko P., et al. Amyloid-β-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761® and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci. 2006;26(50):13102–13113.

24. Költringer P., Langsteger W., Ober O. Dosedependent hemorheological effects and microcirulatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol. 1995;15(4):649–656.

25. Mehlsen J., Drabaek H., Wiinberg N., Winther K. Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers. Clin Physiol Fund Imaging. 2002;22:375-378.

26. Diamond B.J., Shiflett S.C., Feiwel N., Matheis R.J., Noskin O., Richards J.A., Schoenberger N.E. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabii. 2000;81:663-678.

27. Liebgott T., Miollan M., Berchadsky Y., Drieu K., Culcasi M., Pietri S. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res Cardiol. 2000;95:368-377.

28. Akiba S., Kawauchi T., Oka T., Hashizume T., Sato T. Inhibitory effect of the leaf extract of Ginkgo biloba L on oxidative stress-induced platelet aggregation. Biochem Mol Biol Int. 1998;46:1243-1248.

29. Chung K.F., Dent G., McCusker M., Guinot P., Page C.P., Barnes P.J. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet. 1987;1:248-251.

30. Guinot P., Caffrey E., Lambe R., Darragh A. Tanakan inhibits platelet« acth/ating-factor induced platelet aggregation in healthy male volunteers. Haemostasis. 1989;19:219-223.

31. Kudolo G.B., Dorsey S., Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and type 2 diabetic subjects. Thromb Res. 2002;108:151-160.

32. Baf Dit Sollier C., Caplain H., Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol. 2003;25:251-253.

33. Braquet P. Cedemin, a Ginkgo biloba extract, should not be considered as a PAF antagonist [response]. Am J Gastroenterol. 1993;88:2138.

34. Koch E. Inhibition of platelet activating factor (PAR-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine. 2005;12:10- 16.

35. Kohler S., Funk P., Weser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double- blind study in heafthy volunteers. Blood Coagul Fibrinolysis. 2004;15:303-309.

36. Dos Santos-Neto L., de Vilhena Toledo M., Medeiros-Souza P., de Souza G. The use of herbal medicine in Alzheimer’s disease-a systematic review. Evid Based Complement Alternat Med. 2006;3:4:441-445.

37. Bohlken J. Anti-dementia preparations compared. Der Allgemeinarzt. 2003;19:1446-1448.

38. Rowin J., Lewis S.L. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology.

39. ;46:1775–6.

40. Bone K.M. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res. 2008;52:764–71.

41. Gardner C.D., Zehnder J.L., Rigby A.J., Nicholus J.R., Farquhar J.W. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagulation and Fibrinolysis. 2007;18:787-793.

42. Kellermann A.J., Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011 May;31(5):490-502.


Для цитирования:


Пизова Н.В. Безопасность терапии EGb 761® у коморбидных пациентов. Медицинский Совет. 2019;(1):19-23. https://doi.org/10.21518/2079-701X-2019-1-19-23

For citation:


Pizova N.V. Safety of EGb 761® therapy in comorbid patients. Medical Council. 2019;(1):19-23. (In Russ.) https://doi.org/10.21518/2079-701X-2019-1-19-23

Просмотров: 132


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)